Novel Cationic Lipids for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as oligonucleotides, face challenges including susceptibility to nuclease digestion in plasma and limited ability to access the intracellular compartment, leading to inefficient therapeutic delivery.
Innovation Solution
The development of novel cationic lipids that can form lipid nanoparticles with other lipid components, such as neutral lipids and cholesterol, to facilitate the intracellular delivery of nucleic acids by protecting them from degradation and enhancing cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free nucleic acids are administered, then they can potentially reach intracellular targets, but they are susceptible to nuclease digestion in plasma and have limited ability to gain access to the intracellular compartment
Solution Approach 1:
The patent uses cationic lipids as intermediary carriers to deliver nucleic acids into cells. The lipid nanoparticle formulation acts as a mediator that protects nucleic acids from plasma nucleases while facilitating cellular uptake through endocytosis, thereby resolving the contradiction between stability and cellular access
Solution Approach 2:
The patent modifies the physical and chemical parameters of nucleic acid delivery by formulating them into lipid nanoparticles with specific properties (size, surface charge, composition). This changes the delivery parameters to achieve both plasma stability and cellular penetration capability
2Reliability
If lipid nanoparticles are used to protect nucleic acids from degradation, then stability is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent employs composite lipid nanoparticle formulations containing multiple lipid components (cationic lipids, neutral lipids, cholesterol, PEGylated lipids) to achieve stable nucleic acid delivery. This composite approach provides protection from degradation while maintaining manageable formulation complexity through established lipid-based delivery technology
3Productivity
If optimal drug:lipid ratios are achieved for effective delivery, then therapeutic efficacy is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent optimizes delivery efficiency by carefully controlling the drug:lipid ratio as a critical formulation parameter. By establishing specific ratio ranges and using standardized lipid formulations, the patent achieves effective nucleic acid delivery while managing manufacturing precision requirements through parameter optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these novel cationic lipids in lipid nanoparticles improves the stability and delivery efficiency of nucleic acids, providing optimal drug:lipid ratios and ensuring well-tolerated therapeutic outcomes with a favorable therapeutic index.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids with other lipid components have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides
Data Source
AI summary
Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.